Close
Blog & Resources Camargo Blog July 2nd, 2008

505(b)(2)—No Patent, Just Exclusivity

We have all been confronted with the issue of patents and exclusivity for 505(b)(2) product development projects. Financial backers, VC’s, private equity are fixated on the ruggedness of patents – no patent = no money. Biomarin Pharmaceuticals made a presentation at the 2008 BIO conference to encourage others that patents are not always needed. The company representative stated that none of their 3 products had patent protection and that the company relied strictly on exclusivity. In the case of Kuvan, which has orphan exclusivity of 7 years, Biomarin used 3rd party literature to convince FDA to agree to a primary endpoint in their study.


Categories: 505(b)(2) Development

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights